Cargando…

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

OBJECTIVE: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. METHODS: Systematic literature review (SLR), nom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puente, Javier, Anido, Urbano, Climent, Miguel Ángel, Gonzalez-Billalabeitia, Enrique, Lainez, Nuria, Lambea, Julio, Maroto, José Pablo, Mendez-Vidal, Maria Jose, Montesa, Álvaro, Rodriguez, Angel, Zambrana, Curro, González-del-Alba, Aránzazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517999/ https://www.ncbi.nlm.nih.gov/pubmed/33014145 http://dx.doi.org/10.1177/1758835920920067

Ejemplares similares

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
por: Sharma, Aditya Prakash, et al.
Publicado: (2018)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
por: Méndez-Vidal, María José, et al.
Publicado: (2018)

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
por: Méndez-Vidal, María José, et al.
Publicado: (2023)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
por: Juan Fita, María José, et al.
Publicado: (2023)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
por: Puente, Javier, et al.
Publicado: (2019)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials
por: van Soest, Robert J., et al.
Publicado: (2015)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
por: González del Alba, A., et al.
Publicado: (2021)

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
por: León-Mateos, Luis, et al.
Publicado: (2020)

Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group
por: González-del-Alba, Aránzazu, et al.
Publicado: (2022)

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
por: Macaulay, Valentine M., et al.
Publicado: (2023)

Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
por: Guillem, Vicente, et al.
Publicado: (2015)

Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group
por: Redondo, Esther, et al.
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Memoria técnica descriptivo del proyecto de agua potable de la unidad habitacional "El Pital".
por: González Maroto, Miguel angel
Publicado: (1997)

Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
por: Pereira-Veiga, Thais, et al.
Publicado: (2021)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020)

Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning
por: Durán, Ignacio, et al.
Publicado: (2022)

Toutes latitudes /
Publicado: (1993)

Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report
por: Ruiz-Bañobre, Juan, et al.
Publicado: (2016)

Latitudes : 9 poetas de Quebec /
Publicado: (2003)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
por: Conteduca, V., et al.
Publicado: (2017)

Latitude & the magnetic earth
por: Pumfrey, Stephen
Publicado: (2002)

La tasación pericial contradictoria en materia tributaria /
por: Caamaño Anido, Miguel Angel
Publicado: (1995)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

The High Testosterone Concentrations of the Bucks Used in the “Male Effect” Is Not a Prerequisite for Obtaining High Ovarian Activity in Goats from Mediterranean Latitudes
por: Zarazaga, Luis Ángel, et al.
Publicado: (2022)

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
por: Puente, Javier, et al.
Publicado: (2017)

Latitude, Birth Date, and Allergy
por: Wjst, Matthias, et al.
Publicado: (2005)

Latitude, light, clocks and mood
por: Erren, Thomas C, et al.
Publicado: (2011)

Tropical Medicine in the Horse Latitudes
por: Hotez, Peter
Publicado: (2014)

Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group
por: Gómez Caamaño, Antonio, et al.
Publicado: (2021)

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
por: Koroki, Yosuke, et al.
Publicado: (2022)

An adaptive decision-making system supported on user preference predictions for human–robot interactive communication
por: Maroto-Gómez, Marcos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iskr7gqq8ruffsr404ga9r2cn3